• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Former Millennium CEO Deborah Dunsire joins EnVivo as president and CEO

Former Millennium CEO Deborah Dunsire joins EnVivo as president and CEO

July 12, 2013
CenterWatch Staff

EnVivo Pharmaceuticals, developing a range of novel therapies for central nervous system (CNS) diseases, has named Deborah Dunsire, M.D., president and chief executive officer. She also joins the company's board of directors. Dunsire brings more than 25 years of scientific, clinical, operational and commercial experience and biological and pharmaceutical industry leadership to EnVivo.

Dunsire was president and chief executive officer of Millennium Pharmaceuticals from 2005 to 2013. She focused on R&D, driving the development pipeline, fostering a culture of employee engagement and increasing the commercial mindset across the organization to enhance the commercial success of marketed products. The company was acquired by Takeda Pharmaceutical in 2008 for $8.8 billion and became Millennium: The Takeda Oncology Company.

"Deborah's ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled," said Stephen Knight, M.D., chairman of the EnVivo board of directors and president of Fidelity Biosciences. "She joins EnVivo at a transformative point in the company's evolution, as our lead product, EVP-6124, is in phase III clinical trials in schizophrenia and will enter a phase III clinical trial in Alzheimer's disease later this year.”

"CNS diseases, including Alzheimer's disease and schizophrenia, take a toll on patients, families and the healthcare system," said Dunsire. "EnVivo's late-stage lead product candidate and broad pipeline of promising clinical programs present an opportunity to develop new therapies with the potential to make a dramatic impact on patients' lives."

Prior to Millennium, Dunsire led the Novartis U.S. oncology business, playing a role in the development and launch of a number of products. Over 10 years, she increased North American oncology revenues from $50 million to more than $2.2 billion. She served on the U.S. Pharmaceutical Executive Committee at Novartis. Dunsire currently is a board member of Allergan, BIO, the Museum of Science in Boston, Massachusetts General Hospital Research Advisory Council, CancerCare in New York and the Gabrielle's Angels Foundation for Cancer Research.

She has received awards including the 2001 American Cancer Society Excalibur Award, the 2009 Healthcare Businesswomen's Association's "Woman of the Year," the 2011 MassBIO Innovator Award and the 2013 Boston CEO Conference Lifetime Achievement award.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing